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Infection-related preterm birth (PTB) is more common at early gestational ages and is 
associated with major neonatal mortality and morbidity. Abnormal genital tract microflora 
in early pregnancy predicts late miscarriage and early PTB. Accordingly, it is logical to 
consider antibiotics as an intervention. Unfortunately, the conclusions of systematic 
reviews and meta-analyses (SR&MAs) carried out in an attempt to explain the confusion 
over the heterogeneity of individual studies are flawed by the fact that undue reliance was 
placed on studies which: (a) had a suboptimal choice of antibiotic (mainly metronidazole) 
or used antibiotics not recommended for the treatment of bacterial vaginosis (BV) or 
BV-related organisms; (b) used antibiotics too late in pregnancy to influence outcome 
(23–27 weeks); and (c) included women whose risk of PTB was not due to abnormal 
genital tract colonization and hence unlikely to respond to antibiotics. These risks 
included: (a) previous PTB of indeterminate etiology; (b) low weight/body mass index; or 
(c) detection of fetal fibronectin, ureaplasmas, Group B streptococcus or Trichomonas 
vaginalis). While individual studies have found benefit of antibiotic intervention for the 
prevention of PTB, in meta-analyses these effects have been negated by large method-
ologically flawed studies with negative results. As a result, many clinicians think that any 
antibiotic given at any time in pregnancy to any woman at risk of PTB will cause more 
harm than good. Recently, a more focused SR&MA has demonstrated that antibiotics 
active against BV-related organisms, used in women whose risk of PTB is due to abnor-
mal microflora, and used early in pregnancy before irreversible inflammatory damage has 
occurred, can reduce the rate of PTB. This review presents those data, the background 
and attempts to explain the confusion using new information from culture-independent 
molecular-based techniques. It also gives guidance on the structure of putative future 
antibiotic intervention studies.
Keywords: infection, antibiotics, bacterial vaginosis, preterm labour/labor, preterm birth
Abbreviations: AF, amniotic fluid; BMI, body mass index; BV, bacterial vaginosis; CDC, Centers for Disease Control and 
Prevention; CSAIDS, cytokine suppressive anti-inflammatory drugs; CVC, clindamycin vaginal cream; FDA, Food and drug 
Administration; GBS, group B streptococcus; HIV, human immunosuppressive virus; HPV, human papilloma virus; HSV, 
herpes simplex virus; IA, intra-amniotic; IL, interleukin; IV, intravenous; LPS, lipopolysaccharides; MMP, matrix metallo-
proteinases; PG, prostaglandin; PPROM, preterm prelabor rupture of the membranes; PTB, preterm birth; RCT, randomized 
controlled trial; SPTL, spontaneous preterm labor; SR&MA, systematic review and meta-analysis.
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THe iMPORTANCe OF PReTeRM BiRTH
In high-income countries, preterm birth (PTB), particularly 
at early gestations, is the major cause of death and handicap in 
neonates (1–3). Babies born at 22, 24, and 26 completed weeks of 
gestation have an infant mortality rate of 54, 21, and 2%, respec-
tively, and a rate of survival without major morbidity at 365 days 
of 0.02, 14.1, and 45.9%, respectively (2). Approximately 65% of 
babies born between 22 and 26 completed weeks of gestation 
will die on the labor ward or in the neonatal intensive care unit 
and at 30-month follow-up, around 50% will be handicapped 
and in 50% of these, the handicap will be severe. Accordingly, 
at 2.5 years of age only 12–13% will be alive and intact (3). In 
the UK, the cost of hospital readmissions in the first five and 
10 years of life is 20 times greater for those babies born before 
28 completed weeks of gestation compared to those born after 
37 completed weeks (4). In 2007, the Institute of Medicine 
calculated that the annual cost associated with PTB in the USA 
was $26.2 billion comprising medical costs for the baby ($16.9 
billion), labor and delivery costs for the mother ($1.9 billion), 
early intervention programs for children with disabilities and 
developmental delays from birth to age 3 years ($611 million), 
special education services ($1.1 billion), and lost work and pay 
for those born preterm ($5.7 billion) (5). It has been demon-
strated that between 23 and 26 completed weeks of gestation, 
each day of prolongation of pregnancy increases the survival rate 
by 3% (6).
iNFeCTiON AS A CAUSe OF PReTeRM 
BiRTH
Spontaneous preterm labor (SPTL) leading to PTB is now 
recognized as a syndrome caused by a number of pathological 
processes leading to activation of the common terminal pathway 
of parturition (7). The etiology of SPTL is multifactorial but there 
now exists abundant evidence that local or systemic infection or 
inflammation is a major cause, particularly of early PTB (8–10). 
This involves inter alia, prostaglandins (PGs), proinflamma-
tory chemokines and cytokines, as well as pattern recognition 
receptors known as toll-like receptors (11, 12). In addition, the 
relationship between infection and PTB changes as pregnancy 
progresses. Infection in late PTB (34–36 weeks) is unusual but 
is present in most cases in which PTB occurs before 30 weeks 
gestation (13). In addition, the earlier in pregnancy at which 
PTB occurs, the more likely it is to be due to infection (14, 
15). Between 26 and 34 completed weeks of gestation, women 
admitted in SPTL are more likely to have abnormal genital tract 
microflora and chorioamnionitis compared to women delivered 
electively at the same gestational age for feto-maternal indications 
(16–18). Compared with term birth, the prevalence of maternal 
endometritis, chorioamnionitis and neonatal infection is much 
more common following PTB (10, 13, 19, 20). The gestational 
age association of acute chorioamnionitis shows a dramatic 
reduction from 94.4% at 21–24 weeks to 39.6% (25–28 weeks), 
35.4% (29–32  weeks), 10.7% (33–36  weeks), and only 3.8% at 
37–40 weeks (21).
THe PReDiCTiON OF iNFeCTiON-
ReLATeD PReTeRM BiRTH
As pregnancy progresses, the genital tract microflora becomes 
progressively more benign such that by term; the vaginal micro-
flora poses no significant threat to the fetus as it passes through 
the birth canal (22). Although all births before 37 completed 
weeks of gestation are defined as preterm, PTB before 32 weeks 
gestation (2% of all births) accounts for most of the neonatal mor-
tality and morbidity (23). Accordingly, if screening and treatment 
begins at gestations beyond 24 weeks, the opportunity to prevent 
late miscarriage and very early PTB is lost. The main cohort 
studies from Europe, North America, and Indonesia (24–33) and 
three case control studies from the USA, Sweden, and Australia 
(34–36) have used different methodologies to examine the asso-
ciation between abnormal genital tract microflora either in the 
form of bacterial vaginosis (BV) or the presence of BV-associated 
organisms and adverse outcomes of pregnancy. The majority of 
these studies show a statistically significant association between 
abnormal genital tract microflora and late miscarriage and 
PTB. Furthermore, the degree of risk is greater the earlier in 
pregnancy at which abnormal microflora was detected (24). A 
positive screening test for abnormal genital tract microflora at 
26–32 weeks gestation is associated with a statistically significant 
1.4- to 1.9-fold increased risk of PTB (27, 29–32). In contrast, a 
positive result from screening in the second trimester is associ-
ated with a 2.0- to 6.9-fold increased risk of an adverse outcome 
(25–28). In a longitudinal study of women in Indonesia, women 
with BV in early pregnancy had a 21% risk of an adverse outcome, 
compared to only 11% of those who developed the condition later 
in pregnancy (27).
Abnormal Genital Tract Microflora
Due to the polymicrobial nature of vaginal microflora, the defini-
tion of what is normal or abnormal genital tract microflora is very 
difficult. Normal vaginal microflora is assumed to be present in 
the absence of disease. Disease results from the interplay between 
microbial virulence, numerical dominance, and the innate and 
adaptive immune response of the host. Disease is assumed to be 
absent if the woman is asymptomatic, and there are no clinical 
signs of vaginal infectious morbidity. Abnormal vaginal micro-
flora may occur (a) because of a sexually transmitted infection; 
(b) colonization by an organism which is not normally a constitu-
ent part of the vaginal microbial community such as Haemophilus 
influenzae, or Listeria monocytogenes; (c) due to increased viru-
lence or overgrowth of an organism that is normally a constituent 
part of the vaginal microflora, e.g., Escherichia coli; or (d) BV.
The Bacterial vaginosis Syndrome
Disordered vaginal microflora sometimes now referred to as 
“dysbiosis” is most commonly due to BV  –  a polymicrobial 
condition, characterized by a significant decrease in the quantity 
or quality of lactobacilli in association with a 1,000-fold increase 
in the number of other potentially pathogenic organisms such as 
Gardnerella vaginalis, Mycoplasma hominis, Mobiluncus species, 
and other anaerobic organisms. Since many of the organisms 
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associated with BV are quite fastidious, and since BV is a quan-
titative rather than a qualitative change in vaginal microflora, 
qualitative or semiquantitative culture techniques are unhelpful 
for diagnosis. Accordingly, the diagnosis of BV requires quan-
tification of vaginal microbiota (37). With the introduction of 
culture-independent techniques, more sensitive and specific ways 
of diagnosing BV may be developed (38–40). BV affects almost a 
third of women (41). In gynecological practice, BV has been found 
to be associated with the acquisition of STIs such as chlamydia, 
gonorrhea, trichomoniasis, and viral infections (HIV, HSV, and 
HPV), plus a range of morbidities including postabortal sepsis, 
infertility, pelvic inflammatory disease, and posthysterectomy 
vaginal cuff infections. In pregnancy, BV has been associated 
with PTB, preterm prelabor rupture of the membranes (PPROM), 
early, late, and recurrent miscarriage, and postpartum endome-
tritis (24). If BV is detected early in pregnancy, it is associated 
with a five to sevenfold increased risk of SPTL and PTB (25, 26). 
A longitudinal study in pregnancy has demonstrated that only 
2% of women who did not have BV in the second trimester will 
develop BV by 34 weeks. In contrast, 50% of women who had BV 
in the second trimester will still have BV at 34 weeks (42).
New Information from Culture-Independent, 
Molecular-Based Techniques
Recent evidence from cultivation-independent molecular-based 
techniques has demonstrated that BV is not a single entity but 
a syndrome (the BV syndrome) of different sub-types with dif-
ferent etiologies, different microbial communities, and hence 
different responses to antibiotics and, in all likelihood, different 
subsequent phenotypical outcomes from normal term birth to 
late miscarriage, very early PTB, PPROM, or preterm stillbirth 
(38). Such new information clarifies why the etiology remains 
unknown, why the microbiology of BV differs from case to case, 
and why the response to antibiotics remains inconsistent. It 
would also explain why the phenotypic outcome of pregnancy 
differs from case to case, ranging from a normal outcome to a 
very early PTB or late miscarriage. A better understanding would 
help to limit the administration of antibiotics for the prevention 
of infection-related PTB to those antibiotics that are known to be 
effective in women with objective evidence of abnormal vaginal 
microflora and use these antibiotics early in pregnancy before 
inflammation and tissue damage has occurred (43).
ANTiBiOTiCS FOR THe PReveNTiON OF 
iNFeCTiON-ReLATeD PReTeRM BiRTH
This review reflects the use of prophylactic antibiotics used early 
in pregnancy for the prevention of PTB and does not cover the 
management of PPROM, which may be a cause, or a result of 
infection and probably a combination of the two. The literature 
pertaining to the use of antibiotics following PPROM is legion 
and so may be the subject of a separate review.
We know that abnormal vaginal colonization in early preg-
nancy is predictive of PTB (24, 25, 27–36). Accordingly, it is 
logical to consider the use of antibiotics for the prevention of 
infection-related PTB. Unfortunately, antibiotic studies have 
chosen different: (a) risk groups; (b) diagnostic methods; (c) 
degrees of abnormal vaginal colonization; (d) antibiotic dose 
regimens and routes of administration; (e) women with different 
host susceptibilities and hence host response; (f) gestational age 
at time of treatment; (g) outcome parameters; and (h) definitions 
of success (44–62). Understandably, the results of such studies are 
conflicting. A number of systematic reviews and meta-analyses 
(SR&MAs) of these studies have been conducted and updated 
(63–74). However, SR&MAs are retrospective analyses of pooled 
data that are only as good as the quality of studies included (75). 
Due to the aforementioned limitations of the studies published to 
date, the conclusions derived from these SR&MAs are also limited 
and should not be used to provide guidelines or make recom-
mendations for the use or change of practice (75). Similarly, until 
recently, none of the SR&MAs on the use of antibiotics for the 
prevention of infection-related PTB has simultaneously addressed 
the optimal choice of agent, the choice of patient, and the timing 
of intervention. If antibiotic intervention is to be successful in 
reducing the incidence of PTB, these antibiotics (a) should be 
active against those organisms known to be associated with PTB, 
(b) should only be used in women with abnormal genital tract 
microflora, and (c) should be used early in pregnancy before 
infection and inflammation have had an opportunity to cause 
irreversible damage which will inevitably lead to SPTL and PTB.
Choice of Antibiotic
The Centers for Disease Control and Prevention (CDC) do not 
recommend erythromycin or coamoxiclav for the treatment of 
BV. Their recommendation is to use either metronidazole or 
clindamycin, orally or vaginally (76). Like macrolide antibiotics, 
clindamycin has anti-inflammatory properties (77–81) and has 
a broader range of activity against BV-related organisms such 
as species of Mobiluncus and the genital mycoplasmas (82–87). 
Metronidazole and other nitro-imidazoles are inactive in vitro 
against BV-associated organisms such as M. hominis, G. vagi-
nalis, Ureaplasma urealyticum (88, 89), and Atopobium vaginae 
(90, 91). In addition, they have little or no activity against other 
aerobic organisms such as Staphylococcus aureus or species of 
Streptococci. However, metronidazole has a similar treatment 
success rate as clindamycin in  vivo (76). This suggests one or 
both of two possible mechanisms. Firstly, in  vivo, BV-related 
organisms may be sensitive to the hydroxy-metabolite of met-
ronidazole. Alternatively and more likely, metronidazole acts 
indirectly by destroying anaerobes which provide nutrients to 
other BV related organisms such as G. vaginalis or A. vaginae 
(92). Molecular-based studies have indicated a far greater diver-
sity of microorganisms associated with BV than has been evident 
from culture-dependent techniques (38). These organisms form 
different communities that may be anaerobe dominated or G. 
vaginalis and A. vaginae dominated. Other abnormal subtypes 
may be due to mixed organisms or perhaps due to a subtype 
caused by sexual transmission (38). Accordingly, it is possible 
that those sub-types of BV in which anaerobes are dominant are 
more successfully treated by metronidazole. In contrast, in other 
subtypes where anaerobic organisms are not dominant, metro-
nidazole may be less effective. Finally, clindamycin may be active 
against both metronidazole-sensitive sub-types but also against 
November 2015 | Volume 6 | Article 5664
Lamont Antibiotics to Prevent Preterm Birth
Frontiers in Immunology | www.frontiersin.org
a wider range of BV sub-types with different microbial com-
munities. It should be noted that while M. hominis is extremely 
sensitive to clindamycin, U. urealyticum is only weakly sensitive 
to clindamycin (87, 93).
Effect on Lactobacilli
When comparing clindamycin with metronidazole, the case for 
metronidazole and against clindamycin is often given that met-
ronidazole conserves vaginal lactobacilli, whereas clindamycin 
destroys them. However, phage virus colonization of lactobacilli 
is associated with BV, and it has been postulated that diet acquired 
phage viruses, may be induced to become lytic by a factor related 
to sexual activity, or alternatively that Lactobacillus phages may 
be directly inoculated into the vagina from sexual partners (94). If 
phage virus colonization of lactobacilli is present, metronidazole 
may be perpetuating rather than curing BV, whereas the opposite 
would be true with clindamycin.
PREMEVA1 Trial
In 2013, an abstract presented orally to the Society for Maternal–
Fetal Medicine was published on-line. http://dx.doi.org/10.1016/j.
ajog.2013.10.036. The PREMEVA1 trial was a French multicentre 
randomized controlled trial comprising 2,869 low-risk women 
randomized to receive clindamycin or placebo before 15 weeks’ 
gestation. In the placebo group, late abortion/very preterm spon-
taneous delivery rate (12–32 weeks) did not differ significantly 
between the clindamycin and placebo groups. Requests for details 
of the study have elicited no response. Accordingly, at the time 
of completion of this manuscript, no peer-reviewed, full-study 
report could be found on any of the appropriate search engines. 
This being the case, the risk of bias cannot be assessed and, until 
the details of the study are fully available, it is difficult to comment 
on the significance of the findings and these should not be used 
to influence guidelines.
Route of Administration of Clindamycin
The choice between oral clindamycin or clindamycin vaginal 
cream (CVC) to treat abnormal genital tract microflora/BV in 
pregnancy needs to be addressed. Vaginal administration is the 
most direct and efficient route of administration of antibiotic to 
the site of the heaviest bacterial load. In contrast, we know that 
BV is associated with subclinical endometritis (95). Accordingly, 
if vaginal microorganisms have already gained access to the 
choriodecidua, they may not be treatable by CVC, and systematic 
therapy may be necessary. To the authors knowledge, no study 
has studied the simultaneous combined use of CVC and oral 
clindamycin.
The Potential for Newer Macrolide Antibiotics
More data are now available on azithromycin and a new antibi-
otic, solithromycin, that may be considered candidate antibiotics 
in future intervention studies. In a SR&MA, macrolides and 
clindamycin administered during the second trimester of preg-
nancy were associated with a reduction in the rate of PTB (96). 
Second trimester metronidazole used alone was associated with 
an increased risk of PTB in a high-risk population. Like many 
other SR&MAs, studies were included where the risk of PTB 
was positive fetal fibronectin, urogenital mycoplasma infection, 
previous PTB of unqualified phenotype, or prepregnancy weight 
of <50 kg. In addition, while azithromycin and clarithromycin 
were included in the search, the only macrolide included was 
erythromycin (96). In a RCT of interconceptional antibiotics to 
prevent PTB, neither azithromycin nor metronidazole was of any 
benefit in reducing the subsequent rate of PTB (97).
Two recent studies from Malawi tested the effect of prophy-
lactic azithromycin on the subsequent rate of PTB. In a high-risk 
population, routine prophylaxis with azithromycin showed no 
benefit, but this population was unselected (high risk of poor 
pregnancy outcome but not specifically PTB), and no objective 
evidence of infection-related risk of PTB was sought (98). Also 
in Malawi, a RCT of intermittent treatment of maternal malaria 
and reproductive tract infection with monthly sulfadoxine-
pyrimethamine plus two doses of azithromycin was associated 
with a significant reduction in PTB and low birth weight (99).
Solithromycin is a new antibiotic that is highly potent against 
ureaplasmas and mycoplasmas and other antibiotic resistant 
organisms. In an animal study, combined intra-amniotic (IA) 
and intravenous administration of solithromycin resulted in 
effective concentrations of solithromycin in amniotic fluid (AF) 
and maternal and fetal plasma, leading the authors to conclude 
that solithromycin may have promise in future for the prevention 
of PTB (100). Subsequent studies showed that a 4-day course of 
solithromycin eradicated IA Ureaplasma parvum infection in the 
same sheep model (101).
Choice of Patient
Women with BV (Nugent score 7–10) respond better to clindamy-
cin than women with intermediate microflora (Nugent score 4–6). 
Accordingly, prophylactic antibiotics to prevent infection-related 
PTB should only be given to women with objective evidence of 
abnormal vaginal colonization such as BV (37). Without such 
evidence, treatment may disrupt, rather than treat, abnormal 
microflora. In many antibiotic intervention studies, the indication 
for administration of prophylactic antibiotics was previous PTB. 
There is no doubt that previous PTB is a known risk factor for 
subsequent PTB (102, 103). However, a previous PTB may have 
been for feto-maternal indications, such as antepartum hemor-
rhage and fulminating pre-eclampsia. Such indications would not 
place a subsequent pregnancy at risk of infection-related PTB and 
consequently are unlikely to benefit from antibiotic prophylaxis. 
Such studies (104), have been erroneously cited as evidence that 
antibiotics have no role in the prevention of PTB (105). Only a 
small portion of such women (even those with BV) may be at risk 
for PTB. Better diagnostic or predictive methods are required to 
improve our ability to identify those women who would be most 
likely to benefit from treatment with antibiotics.
Pharmacogenetics
Pharmacogenetics is also an important consideration (106). 
Metronidazole used in mainly Black or Hispanic women in 
North America has not shown benefit (52). In contrast, in 
predominantly White North European women, five studies 
using clindamycin have shown benefit (43). Black or Hispanic 
women may have a genetic predisposition to mount a damaging 
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inflammatory response to the challenge of BV, while predomi-
nantly white Northern European women do not. Alternatively, 
in predominantly white Northern European women, the inflam-
matory response may be sufficiently less rigorous to allow time 
for antibiotic therapy to be of benefit. Finally, it may be that some 
women with a prior PTB have a genetically non-infectious risk 
of PTB under which circumstances their propensity to deliver 
preterm will exist with or without BV and hence would not be 
expected to respond to antibiotic treatment. These studies and the 
findings of racial differences in the vaginal microbiome highlight 
the importance of tailoring antibiotic treatment approaches for 
different racial groups and controlling for race in clinical trials.
Treatment of Symptomatic or Asymptomatic 
Pregnant Women with BV
Symptomatic pregnant women with BV should be treated even 
if they are at otherwise low risk of PTB. The management of 
asymptomatic women with BV who do not have other risk factors 
such as a previous BV-related PTB is less well accepted. Since BV 
is an independent risk factor for PTB, one could argue that any 
woman with BV (symptomatic or asymptomatic) is at a signifi-
cant twofold increased risk of PTB, if BV is detected at or beyond 
24 completed weeks of gestation. This is the same risk associated 
with smoking which is considered significant enough to merit 
intervention. In contrast, if BV is detected before 16 weeks gesta-
tion, there is a five to sevenfold increased risk of PTB (see the 
Section on The Prediction of Infection-Related Preterm Birth). 
If one relies on previous PTB as a risk factor for subsequent PTB 
in women with BV, it is essential to record the phenotype of that 
previous PTB. If the previous PTB was iatrogenic, because of 
twins, APH, or pregnancy-induced hypertension/preeclampsia, 
it may not be relevant in women with BV. Similarly, if the previous 
PTB was unexplained apart from a maternal weight <50 kg or a 
BMI <18 kg/m2 then the detection of BV may be irrelevant. As 
more information becomes available from molecular-based, cul-
tivation-independent techniques, the identification of sub-types 
of BV, the different etiologies of each, the different microbiology, 
the different response to antibiotics, and the different phenotypic 
outcomes may address this concern.
Timing of Antibiotics
Abnormal genital tract microflora in early pregnancy, even if this 
reverts to normal, is still associated with late miscarriage and 
PTB (44) suggesting that whatever damage is done by infection 
and inflammation, this occurs early and persists (44, 107–113). If 
antibiotics are used late in pregnancy when inflammatory tissue 
damage may have already occurred, and there are already irre-
versible changes in the cervix, myometrium, decidua, placenta, 
and extraplacental membranes, then antibiotics are unlikely to 
be of benefit. Accordingly, concern has been expressed that under 
these circumstances, antibiotics may cause more harm than good 
(114–120). Hence, it may be argued that antibiotics should be 
used early in pregnancy before infection/inflammation can cause 
irreversible damage that ultimately leads to SPTL and PTB. In 
their recommendations for the treatment of BV in pregnancy, 
the CDC treatment guidelines advise the use of oral or vaginal 
metronidazole or oral clindamycin (76). However, it was noted 
that the late administration of CVC up to 32  weeks gestation 
was associated with subsequent adverse outcomes, such as low 
birth weight and neonatal infection (28, 48, 51). As a result, the 
guidelines recommend that CVC should only be used in the first 
half of pregnancy (76).
Gene–Environmental Interaction
Many diseases like PTB are due to a combination of genetic 
susceptibility and environmental exposure. A woman may have 
the environmental exposure (BV), but if she does not have the 
genetic susceptibility (gene polymorphism) to mount a damaging 
inflammatory response then little harm may occur. Conversely, 
a woman may possess the gene polymorphism to mount a 
damaging inflammatory response, but if she does not have envi-
ronmental exposure (BV) then damage may not occur. However, 
when both susceptibility and exposure are present, the risk of 
an adverse outcome will be increased, and this is referred to as 
the gene–environmental interaction (121). Abnormal vaginal 
microflora or infection leads to adherence, invasion, and host 
inflammatory response. That response may be appropriate result-
ing in tissue repair and healing. Alternatively, the response may 
be exaggerated (hyper-response) resulting in tissue damage from 
increased production and release of proinflammatory cytokines. 
Conversely, the response may be inadequate (hyporesponse) 
leading to overwhelming infection. Both a hyper-response and a 
hypo-response may result in mortality and morbidity due to tis-
sue damage. If antibiotics are used late in this process, it may not 
be possible to prevent irreversible tissue damage, morbidity, and 
mortality. In contrast, if antibiotics are used early, before tissue 
damage occurs, this damage might be prevented. Accordingly, the 
earlier the gestational age at which clindamycin is administered to 
women with objective evidence of risk of infection-related PTB, 
the more likely it is to be able to demonstrate a reduction in the 
rate of PTB (43).
Potential for the Use of Anti-inflammatory Agents as 
Adjunctive Treatment
The potential for adding to antibiotics an anti-inflammatory agent 
which targets the NF-κB and p38 MAPK (cytokine suppressive 
anti-inflammatory drugs [CSAIDs]) that block cytokine signal-
ing for the prevention and treatment of inflammation-induced 
PTB shows promise and has been comprehensively reviewed 
elsewhere (122). In an ovine model, IA administration of a single 
dose of CSAID suppressed the lipopolysaccharide-induced IA 
inflammatory response with minimal fetal effects (123). Several 
animal model studies have shown additional benefit of antibiotic 
cotreatment with anti-inflammatory agents. In the rhesus mon-
key, following IA inoculation of U. parvum, azithromycin plus 
dexamethasone and indomethacin was able to prolong pregnancy 
and prevent advanced fetal lung injury (124). Similarly, to deter-
mine whether treatment with ampicillin/dexamethasone/indo-
methacin (AMP/DEX/INDO) delayed PTB induced by IA Group 
B streptococcus (GBS) inoculation in rhesus monkeys, ampicillin 
alone eradicated GBS but uterine activity, AF cytokines, PGs, and 
matrix metalloprotein (MMP)-9 remained elevated. In contrast, 
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the combination of AMP/DEX/INDO suppressed interleukin-
1β, TNF-α, PGE2, and PGF2α but did not alter MMP expression 
or chorioamnionitis. The combination of AMP/DEX/INDO 
suppressed inflammation and significantly prolonged gestation 
(125).
Rescreening and Retreating with 
Antibiotics
In many antibiotic intervention studies there has been incon-
sistency of rescreening and retreatment in which persistent or 
recurrent BV occurs in ~10–30% (43). Using stringent diagnostic 
criteria (BV on Nugent score together with all four elements 
of Amsel’s clinical composite criteria), 70.8% of women who 
received CVC were cured/improved at 20–24 days post-treatment 
compared to only 12% in the placebo group. Recurrence rates 
in those CVC patients successfully treated were ~6% at 6 weeks 
postbaseline and 10% at 28–34 weeks. Of the 29.2% of women 
who failed to respond to the first 3-day course of CVC and who 
were therefore retreated with a 7-day course of CVC, 32.6% and 
51.2% were cured/improved at 20–24 days postretreatment and at 
28–34 weeks gestation, respectively (126). Accordingly, rescreen-
ing and retreating in pregnancy may be helpful since an initial 
course of CVC cured or improved BV in 88% of women, and 
a second course some 3–6 weeks later was still able to cure or 
improve BV in 50% of those who still had the condition (127).
CRiTiCAL Review OF THe LiTeRATURe 
ON THe USe OF ANTiBiOTiCS TO 
PReveNT iNFeCTiON-ReLATeD 
PReTeRM BiRTH
As discussed earlier, the majority of the SR&MA that consider 
the use of antibiotics for the prevention of PTB inappropriately 
merged clindamycin and metronidazole studies together rather 
than considering them separately. Those studies that initially 
considered clindamycin and metronidazole studies separately 
then erred by combining the two antibiotics when considering 
the gestational age at treatment (63, 66, 74). While the majority of 
studies included in the SR&MA comprised women with objective 
evidence of BV, two meta-analyses included studies where the 
risk-status or entry criteria was measured by other parameters 
unrelated to BV. These included parameters, such as positive 
fetal fibronectin test, previous PTB, and detection of GBS, U. 
urealyticum, or trichomonas (66, 74). Using these SR&MAs, it 
can be concluded that if inappropriate antibiotics are used at late 
gestations, in women without objective evidence of abnormal 
vaginal bacterial colonization, there is no benefit with respect 
to the prevention of infection-related PTB. However, concerns 
have been expressed that if these SR&MAs are not interpreted 
carefully, they will be erroneously cited as evidence that any anti-
biotic, given to any pregnant woman, at any gestational age will be 
unhelpful in preventing PTB. For this interpretation, caution has 
been urged (114–120, 128–130). Two large studies are regularly 
cited in SR&MA as evidence that antibiotics are of no benefit for 
the prevention of PTB: the National Institutes for Child Health 
and Human Development (NICHD)/Maternal Fetal Medicine 
Network Units (MFMU) study (52) and the ORACLE II study 
(131, 132). Despite their faults (see below), these studies mark-
edly outweigh all other studies in SR&MA and hence strongly 
influence conclusions.
The NiCHD/MFMU (2000) Study
This study screened 29,626 women (52) of which 6,540 were 
positive solely for BV without other conditions, such as tricho-
moniasis. From these, the recruitment was low with only 1,936 
(29.6%) randomized to receive either metronidazole or placebo. 
Of the 4,604 exclusions, 999 were excluded for reasons recorded 
as “other.” Most SR&MAs classify this study as having been in a 
“low-risk population” yet 85% of the population was either Black 
or Hispanic. As a part of the methodology, up to 8 weeks could 
elapse between screening and initiation of treatment. During 
this delay, the grade of microflora on Gram stain changed in 
25% of women (115). Metronidazole was administered as a once 
only 2  g oral dose and unsurprisingly, vomiting occurred in a 
high percentage of women. Under such circumstances, the 2 g 
oral dose was repeated 2 days later. With no objective measure 
of compliance, such as metronidazole blood levels, the number 
of women who took the repeat course remains undocumented. 
Importantly, there was an inexplicable 37% placebo effect while 
BV remained in 22% of the metronidazole group and 63% of the 
placebo group at 1 month. This suggests confounding by factors, 
such as a lack of effectiveness of metronidazole in the treatment 
group or spontaneous resolution in the placebo group. Finally, 
treatment was started late in pregnancy with 44% treated after 
20 weeks gestation, and no women were treated before 16 weeks 
gestation.
ORACLe ii Study
The ORACLE II trial is commonly cited as evidence that antibiotic 
treatment does not prevent PTB. More accurately, the ORACLE 
II trial should be cited as demonstrating that if inappropriate 
antibiotics are given to women too late in pregnancy with no 
objective evidence of abnormal vaginal microflora then they are 
ineffective in preventing infection-related PTB. Accordingly, in 
any SR&MAs related to the use of antibiotics to prevent infection-
related PTB, the Oracle II study should be excluded; sadly, this 
is not the case and due to the numbers involved the study has a 
strong weighting such that the positive results of other studies are 
negated. Erythromycin and coamoxiclav were used in this study 
(132) because of the perceived importance of Ureaplasmas in 
neonatal infectious morbidity (133), but neither is recommended 
for the treatment of BV (76). It is notable that erythromycin, while 
being effective against Ureaplasma spp., exhibits minimal passage 
across the placenta and hence does not reach effective concentra-
tions in AF. Hence it is not effective in eradicating intrauterine 
Ureaplasma infections. Women with known infections were 
excluded, and the trial protocol required no objective evidence 
of abnormal vaginal colonization for the diagnosis of BV (37). 
Without objective evidence of abnormal vaginal microflora, at 
least 60% and probably more at this late gestation were not in 
infection-related SPTL. There are also serious concerns about 
the accuracy of diagnosis of SPTL. Only 50% of cases required 
tocolytics and around 90% of women were still undelivered after 
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48  h. Approximately 85% of women remained undelivered by 
7  days and the mean gestational age at delivery was 38  weeks. 
The timing of administration of antibiotics was also questioned 
since the intervention occurred after SPTL had begun. Finally, in 
the 7-year follow-up report of the ORACLE II study (131), the 
assessment of cerebral palsy has been questioned. The assessment 
only applied to the two-thirds of cases that were recruited from 
the UK rather than the Republic of Ireland, and the assessment 
of cerebral palsy was based upon telephone calls to the parents, 
and in some cases, parent completed postal questionnaires rather 
than an objective, structured neurobehavioral assessment by 
skilled healthcare professionals.
Cochrane Systematic Review  
(Updated 2013)
The recently updated Cochrane Review (63, 74) is already being 
cited as evidence that antibiotics are unhelpful for the prevention 
of PTB. The updated review (74) is extensive and contains data 
from 21 trials and reports 57 different analyses. These numbers are 
necessary because the included studies used different risk groups, 
diagnostic methods, degrees of abnormal microflora, antibiotic 
dose regimens and routes of administration, host susceptibilities, 
host response, gestational age at time of treatment, outcome 
parameters, and definitions of success (44–53, 55–58) resulting 
in different results. However, in contrast to the systematic review 
reported below (43), the Cochrane Review (74) includes studies 
which used antibiotics that are not recommended for the treat-
ment of BV and importantly did not consider the effect of phar-
macogenetics (106) as outlined in the Section above “Choice of 
patient.” In addition, the review included women with a previous 
PTB of non-infectious etiology. It did not differentiate between 
clindamycin and metronidazole when assessing the benefit of 
treatment before 20 weeks gestation. The review selected studies 
of pregnant women with either “BV” or “intermediate microflora” 
without considering that these are different entities with differing 
rates of response to antibiotics (134). Finally, the review did not 
include recent evidence of the benefit of rescreening and retreat-
ing BV in pregnancy (127) and the title of the Review was “the 
treatment of bacterial vaginosis in pregnancy” and should not 
have been used to comment on the prevention of preterm birth.
AJOG Systematic Review 2011
To address the deficiencies of existing SR&MA with respect to 
the optimal choice of agent, the choice of patient, and the tim-
ing of intervention, we performed a SR&MA of clindamycin use 
before 22 weeks gestation in women with abnormal genital tract 
microflora (43). The hypothesis of the review was that previous 
SR&MA on the use of antibiotics used prophylactically for the 
prevention of PTB or their individual studies were flawed by the 
fact that undue reliance was placed on studies in which suboptimal 
antibiotics (mainly metronidazole) were used. They were also 
flawed by the fact that antibiotics were used too late in pregnancy 
to influence outcome (23–27 weeks gestation) and used in women 
whose risk of PTB was not due to BV but due to some other mark-
ers not directly related to infection. Conversely, the hypothesis of 
the SM&MA was that antibiotics that are active against BV or 
BV-related organisms that are appropriately used in women whose 
risk of PTB is due to abnormal genital tract colonization and that 
are administered early in pregnancy before irreversible inflam-
matory damage occurs can reduce the rate of PTB. The primary 
outcome of the studies included in this SR&MA was spontaneous 
PTB at <37 completed weeks gestation and late miscarriage. These 
were chosen because they were used in most meta-analyses that 
evaluated preventative strategies for PTB. In the meta-analysis, 
the RR for delivery <33 weeks was 0.44 (95% CI: 0.41–1.41; nine 
versus four cases), but due to the low numbers this was not statisti-
cally significant. Although the reduction was consistent with the 
beneficial effect of clindamycin seen in the later gestational age 
groups, further research is required to confirm efficacy at lower 
gestations. The SR&MA demonstrated that when clindamycin 
was compared to controls, administration before 22 weeks gesta-
tion to women with objective evidence of abnormal genital tract 
microflora was associated with a significant reduction in the rates 
of PTB and late miscarriage by 40 and 80%, respectively.
Secondary Outcome Variables
The secondary outcome variables demonstrated that of those 
infants born preterm, low birth weight occurred in 20% of those 
who received clindamycin compared to 80% of those who received 
no treatment (P < 0.009). There was also a 32.5-day difference in 
the mean prolongation of pregnancy in favor of clindamycin com-
pared with no treatment (P < 0.024) (62). In women with the high-
est Nugent Score of 10, late miscarriage and PTB occurred in 5.4% 
of those who received clindamycin compared to 35.7% of those 
who received placebo (60). Finally, the rate of late miscarriage or 
PTB was 28% in those women with persistent BV compared to 10% 
in those in whom BV was cured (OR = 2.9; 95% CI = 1.3–5.2), and 
the rate of late miscarriage or PTB was 15% in women with cured 
but recurrent BV, compared to only 2% in those women whose BV 
was cured with no recurrence (OR = 9.3; 95% CI = 1.6–53.5) (54).
SAFeTY OF AND ReSiSTANCe TO 
ANTiBiOTiCS iN PReGNANCY
The safety of antimicrobials in pregnancy has recently been 
reviewed (135). A common response to the case for antibiotic 
use to prevent infection-related PTB is that we already use 
antibiotics too frequently in pregnancy. However, few can cite 
local/personal audit of such practice. Accordingly, we reported 
a large, population-based study comprising nearly 1  million 
Danish women which demonstrated that >40% received antimi-
crobials at some stage during pregnancy (136). We felt that this 
might be an underestimate because Denmark, like other Nordic 
countries, is cautious about the use of antibiotics in pregnancy. 
In addition, the Registry used included only antibiotics obtained 
by prescription in the community. Our response would be that 
by employing a more focused approach to the use of antibiotics 
for the prevention of infection-related PTB we would, in effect, 
be reducing the indiscriminate use of antibiotics already demon-
strated. The development and introduction of new antibiotics has 
declined markedly and drug-resistant bacteria are more common 
in hospitals and the community. In 2013, a report by the CDC 
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reported that >2,000,000 people each year suffer from antibiotic 
resistant infections and >23,000 die as a result. Unfortunately, 
the number of new drugs to replace ineffective antibiotics is not 
adequate to meet current needs, and many major pharmaceuti-
cal companies have abandoned development of new antibiotics, 
focusing instead on new, long-term medications, such as statins 
and antihypertensives that produce greater profits. As an incen-
tive for manufacturers to develop new antibiotics, in 2012, the 
Generating Antibiotic Incentives Now (GAIN) legislation was 
signed into US law as a part of the FDA Safety and Innovation Act. 
This legislation extends by 5 years the exclusivity period during 
which time those antibiotics that treat serious or life-threatening 
infections can be sold without generic competition. Drugs that 
fall under the GAIN provisions receive fast track and priority 
review status and undergo an expedited regulatory approval 
process with the FDA (137).
Neonatal Gut Microbiome and Atopic 
Disease
New information from The Human Microbiome Project using 
cultivation-independent, molecular-based techniques has 
revolutionized our understanding of the vaginal microbiome in 
pregnancy and the non-pregnant state (38). The immune system 
is primed in utero and modified after birth. Accordingly, the use 
of antibiotics during pregnancy or the neonatal period may cause 
disruption of the developing neonatal gut microbiome, result-
ing in a failure of maturation of the immune response and the 
subsequent development of asthma, allergy, and atopic disease 
(138–141). This has led to new initiatives such as the Neomune 
Project publicly funded by the Danish Council for Strategic 
Research whose objective is to develop new diet and gut micro-
flora treatments for new born infants.
eviDeNCe-BASeD MeDiCiNe
Guidelines issued by professional bodies, such as the Royal 
College of Obstetricians and Gynecologists, use a systematically 
developed standardized methodology (http://www.rcog.org.
uk/guidelines) and a standardized grading scheme for the 
classification of evidence levels and grades of recommenda-
tions. Other organizations or governing bodies that produce 
guidelines use very similar methodology and schemes. The 
highest classification of evidence is 1++, which is defined as 
“high-quality meta-analyses, systematic reviews of randomized 
controlled trials or randomized controlled trials with a very low 
risk of bias.” The highest grade of recommendation is A which 
is defined as “At least one meta-analysis, systematic review or 
randomized controlled trial rated as 1++ and directly applicable 
to the target population; or a systematic review of randomized 
controlled trials or a body of evidence consisting principally of 
studies rated as 1+ directly applicable to the target population 
and demonstrating overall consistency of results.” Those who 
provide guidelines and recommendations base these on some 
SR&MAs of some RCTs as a result of which they may claim to 
be “evidence based.” SR&MAs are only as good as those stud-
ies included and if the questions asked about the populations, 
interventions, and outcomes are wrong or misdirected they 
should not be used to make recommendations or provide clini-
cal guidelines (75). The Cochrane database is often the default 
of many clinicians looking for information, yet Cochrane is not 
without its faults, particularly in the area of PTB (142). Most 
SR&MAs of antibiotics for the prevention of PTB (Cochrane 
or otherwise) ask the question “In women at risk of PTB 
(population), do antibiotics (intervention) reduce the rate of 
PTB (outcome).” It is not surprising, therefore, that the updated 
Cochrane review of 2013 (74) contained data from 21 trials and 
required 57 different analyses because the included studies used 
different risk groups, diagnostic methods, degrees of abnormal 
microflora, antibiotic dose regimens and routes of administra-
tion, host susceptibilities, host response, gestational age at time 
of treatment, outcome parameters, and definitions of success 
(44–53, 55–58) resulting in different results. In contrast to other 
SR&MAs, in the AJOG SR&MA (43), the question was much 
more focused: “In pregnant women at risk of PTB of infectious 
etiology (population) does clindamycin administered before 
22 weeks gestation (intervention) reduce the rate of PTB or late 
miscarriage (outcome).”
FUTURe ReSeARCH
Even if the evidence based data is insufficient for some, they 
must at least accept that clinical equipoise exists (the ethical basis 
for medical research that involves assigning patients to differ-
ent treatment arms of a clinical trial) and support a definitive 
randomized controlled trial. The choice of antibiotics (a) should 
be active against those organisms known to be associated with 
PTB, (b) should only be used in women with abnormal genital 
tract microflora, and (c) should be used early in pregnancy before 
infection and inflammation can cause irreversible tissue damage 
which will inevitably lead to SPTL and PTB. Such a study should 
contain genomic, transcriptomic, proteomic, and metabolomic 
studies to assess the vaginal microbiome, the vaginal milieu 
created by different microbiomic communities, and the host 
response of the individual to each sub-type of microbiome and 
milieu. PTB per  se is only a surrogate for neonatal outcome. 
Detailed neonatal outcome data with appropriate long-term 
follow-up as well as the number of days gained from treatment 
to delivery should be the primary outcome parameters. Finally, 
different phenotypical outcomes of SPTL and PTB, such as late 
miscarriage, extreme PTB around the limits of viability, PPROM, 
late PTB, preterm stillbirth, and SPTL with intact membranes 
with or without vaginal bleeding should be considered. This is 
because the combination of different vaginal microbial com-
munities, different vaginal milieu, and different host response 
may result in a range of phenotypic outcomes from normal term 
delivery to preterm stillbirth or severe morbidity associated with 
extremely premature birth.
CONCLUSiON
The earlier in pregnancy at which PTB occurs, the more likely 
this is to be due to infection (14). The earlier in pregnancy at 
which abnormal genital tract colonization is detected, the greater 
November 2015 | Volume 6 | Article 5669
Lamont Antibiotics to Prevent Preterm Birth
Frontiers in Immunology | www.frontiersin.org
is the risk of an adverse outcome like late miscarriage or PTB 
(24). Abnormal vaginal microflora in early pregnancy, even if this 
resolves, is still associated with an adverse outcome (44) suggest-
ing that whatever damage is caused by infection, this occurs early 
and persists. Accordingly, if antibiotics are to be used to prevent 
infection-related PTB these should be administered early. New 
evidence from molecular-based culture-independent studies of 
the vaginal microbiome (38) indicates that across the range of 
different microbial communities or sub-types of BV the bacteria 
detected are more likely to respond to clindamycin than metroni-
dazole. Finally, treatment on the basis of the previous PTB should 
be predicated by some measure of infective etiology. Antibiotic 
treatment on the basis of previous PTB of unknown etiology or 
other risk factors for PTB unrelated to abnormal genital tract 
microflora should be discouraged. While individual studies have 
found benefit of antibiotic intervention for the prevention of PTB, 
in meta-analyses, these effects have been negated by large meth-
odologically flawed studies with negative results. While (rightly) 
SR&MAs of efficacy focus on primary outcome parameters, the 
benefits associated with secondary outcomes are important and 
should not be ignored (vide supra Secondary outcomes) (43). At 
worst, equipoise exists with respect to the early use of clindamycin 
for the prevention of infection-related PTB. If a further, hopefully 
definitive trial is deemed necessary, this should be of a design and 
contains molecular omic data which will give a greater under-
standing of the underlying systems biology and mechanisms 
involved so that the same mistakes of previous flawed studies are 
not repeated. In the meantime, the use of antibiotics in pregnancy 
for the prevention of PTB should be restricted to those who are 
most likely to benefit.
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